Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing Instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, During the second year of this project we have made further strides toward the broad goals of this project to develop improved bloodbased methods for prostate cancer diagnostics and to better understand the nature of the changes in the blood of prostate. cancer patients. The first year of the project was used to lay some of the fundamental foundations for the later work: we answered valuable questions about the optimal strategies for using antibody microarrays, we better characterized the performance of the antibodies, and we significantly improved the experimental protocols. The work of the second year has built upon those developments and has resulted in several accomplishments. We further developed and improved the methods by instituting improved quality control for the antibodies, by developing an improved ability to run samples in high-throughput, and by identifying a better-performing microarray surface. We performed initial profiling studies on serum samples from prostate cancer patients and controls using antibody microarrays containing 96 or 91 antibodies. The preliminary analyses identified areas of the technology that needed improving or that required an alternate strategy. We have addressed and solved the potentially confounding influence of species-dependent, non-specific binding, and we are using the alternate strategy of sandwich immunoassays for a select set of low-abundance analytes. The early analyses also identified several interesting differences between the patient groups, which will be further investigated. Our improved methods are currently being used for comprehensive profiling studies of our serum Sample sets, and the data from these studies will be analyzed to fulfill the goals of year 3.
The report contains a summary from the second year of work on our project to analyze the variation in protein composition in the sera of prostate cancer patients and controls. The broad goals of this project are to develop markers that aid in the specific diagnosis of prostate cancer and to gain insight into the functional significance of serum composition alterations that are associated with the disease. The project was divided into three tasks. Task 1 related to optimizing and validating the methods that would be used in Task 2. Most of Task 1 has been completed, with one part ongoing for practical reasons described in the report. The goal of Task 2 was to acquire profiles of a wide variety of proteins in serum samples from prostate cancer patients and controls. That task has been completed in initial data sets, yet we are continuing to collect data on the samples to bolster the data we already have. Task 3 concerned the bioinformatics analyses of the data to uncover relationships among the proteins and samples. Initial analyses have been performed, and further analyses will be conducted in year 3 as the data become available. Much more information about the performance of the assay has been gathered, which has led to improvements to the assays or alternate strategies in some cases. The improvements to the methods and the alternate strategies we are using will result in much more complete and valuable data than we otherwise would acquire. We expect very valuable information to be generated from the profiling experiments that are currently underway, and we are on target to complete all tasks at the end of year 3.
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Summary of progress on Task 1
The purpose of the work in Task I was to determine the optimum conditions for taking microarray measurements for each of the antibodies. Most of the work of that task had been completed in year 1. In that year we gained a greater understanding of the requirements for setting optimal serum dilution factors and for measuring multiple serum proteins of varying concentrations with a single dilution. We found that our two-color competitive assay allowed us to accurately measure different proteins of widely varying concentrations, provided the concentration of each protein in the reference solution was approximately matched to the concentration of the corresponding protein in the sample solutions. Therefore, we could measure proteins in the mg/ml range and proteins in the ng/ml range using the same dilution factor and the same detection method. Our two-color rolling circle amplification (TC-RCA) method was preferable to non-amplified detection. We performed some additional work on Task I in year 2, as described below. The statement of work for Task 1 is below, with a detailed description of the progress on each point following. Step a. This step was essentially finished in year 1. In year two, we added about seven new antibodies to the experiments. We added a quality control step for every antibody, in which every antibody gets analyzed on a reducing and non-reducing gel. This step allows us to confirm that each antibody is intact, is free Step b. In year 1, we determined that as accurate and precise as our direct labeling method. In addition, the linear range was similar, since we were using a competitive assay with a matched reference solution, so we were able to use RCA for the measurement of both high and low abundance proteins, provided the reference concentrations were somewhat matched. That condition is guaranteed by our procedure of using a pool of all the samples as the reference solution. Therefore this subtask was completed, and we elected to use the TC-RCA method at one dilution for our profiling experiments.
Step c. The purpose of this step was to determine if the linear range of detection was different between RCA detection and direct labeling, which then could necessitate the use of two detection methods for every sample--RCA for low-abundance proteins and direct labeling for higher abundance proteins. As described above, we learned that RCA could be used for both high and low abundance proteins because of the performance characteristics of the competitive assay. In year I we further explored the question of optimal dilution factor, and whether each sample should be run at multiple dilutions. We found a minimal advantage in running more than one dilution with the competitive assay. Therefore, this step was completed in year 1, and we will use TC-RCA at one dilution for the initial profiling experiments.
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indicating that C3 may be nonspecifically binding to these performed on a limited set of antigens since purified antigens are only available for common proteins and are often very expensive. Also, as described in the previous progress report, we are focusing our validation efforts on the antibodies that provide useful information in the profiling experiments. It will be more efficient to first screen the performance of the antibodies and then perform the validation studies. The validation of the binding specificity can be performed using multiple methods that we now use routinely in the lab, such as western blots and immunoprecipitations. We expect to do more antibody validations after the next rounds of profiling experiments, which are currently underway. Therefore this aim is ongoing.
Additional progress toward the goals of the project Collection of additional serum samples. In the first year of the project we obtained serum samples from collaborators Dr. Teh at Baylor College of Medicine and Dr. Partin at Johns Hopkins University. 280 samples were received in the first year. In the second year, to complete our sample set and to allow better statistical analysis of multiplexed data, 200 more samples were obtained from Dr. Partin: another 50 each from patients with benign prostatic hyperplasia, organ-confined prostate cancer, "metastatic prostate cancer, and no disease.
Further development of high-throughput sample processing. In year 1 we reported on developments that allowed highthroughput sample processing. This method was important to enhance our ability to run large sample sets. We have further developed those methods. We are now printing 48 microarrays on each microscope slide, and we use our custom-built slide imprinter to imprint hydrophobic wax borders between the arrays, so that a different sample can be isolated on each array. A microscope slide with 48 arrays is shown in Figure 3 . We are now routinely using this format. We are in the process of making the sample labeling and preparation steps more high-throughput and automated, as those steps are the current bottleneck in large studies.
Further improvements in the experimental protocol. A major factor that determines the quality of microarray data is the surface upon which the microarrays are printed. Several different types of surfaces have been demonstrated and are commercially available. In year 1, we primarily used nitrocellulose-coated perform somewhat better than our previous hydrogel slides incubated with a different (PerkinElmer) and poly-l-lysine-coated slides. In that work we serum sample and detected by saw evidence that the FAST slide was not optimal for our TC-RCA. experiments due to high backgrounds and possible high nonspecific binding. Therefore it was important, before continuing with large-scale profiling experiments, to identify the best surface for the experiments.
We performed a systematic comparison of four different surfaces, looking at signal-tobackground ratios, reproducibilities, and detection limits. In dilution series of purified antigens in a BSA background, the FAST slides had higher detection limits than the other surfaces ( Figure 4 ). The S/Bs also were lower. The other surfaces performed well, but a slide coated with an ultra-thin layer of nitrocellulose (Path ., slides, Gentel Biosurfaces) seemed to b. Perform microarray experiments on each of the serum samples in duplicate using direct labeling and in duplicate using signal amplification by RCA. c. Prepare data for analysis: "grid" microarray images and reject weak or poor quality data points. Reject data points that do not fall within the linear range of each detection method.
Step a. Over 300 microarrays each containing 96 antibodies were printed in year one for the initial testing studies and the initial data collection on the clinical samples. In year 2, we printed 492 arrays in 3 prints with 91 antibodies per array. The antibodies on the arrays were slightly different between sets I & 2 and sets 3 & 4, since sets 3 & 4 included some new antibodies and excluded some antibodies that performed poorly earlier or that were discovered by gel analysis (Figure 1) to not be good. We have also printed many arrays for the additional optimization and development work that is described in this report.
Step b. At the end of year 1, 146 samples had been processed in duplicate on antibody microarrays containing 96 antibodies each. The samples were from patients with organ-confined prostate cancer, non-organ-confined prostate cancer, benign prostatic hyperplasia, and no disease. These experiments were performed on arrays printed on nitrocellulose-coated microscope slides from Schleicher & Schuell, using the TC-RCA detection method. In year 2, we continued the profiling studies initiated in year 1. These arrays, containing 91 different antibodies and printed on our new ultra-thin nitrocellulose surface, were used to profile 150 samples, 50 each from organ-confined cancer, BPH, and healthy, in triplicate experiment sets. We chose to use only three classes instead of four to simplify the analysis in the first stage of data collection and because we are most interested in detecting early-stage cancer. One of the experiment sets unfortunately failed due to problems running the experiments, leaving us duplicate experiments on this sample set. Thus we currently have four sets of profiling data: two performed on nitrocellulose-coated slides (sets I & 2), and two performed on ultra-thin nitrocellulose (sets 3 & 4) . The analyses of these data are described under Task 3. All experiments were performed using TC-RCA detection for the reasons described in Task 1.
Step c. This step has been performed for all acquired data. This process is fairly rapid since we have written a software script to automate the process of rejecting low-intensity data points, based on a statistical threshold. Also, we reject data based on a lack of reproducibility between duplicate experiment sets. A 99% confidence threshold in the correlation between the data from the replicate sets is calculated, and data from antibodies not surpassing that threshold are rejected. An example of thresholding the data based on reproducibility is shown in Figure 3 . The correlation between the data from the replicate experiment sets was calculated for each antibody, and a histogram of the correlations was generated. Most correlations were in the 0.8-0.9 range, which is highly reproducible. The dashed line gives the approximate threshold for 99% confidence correlation (the threshold varies depending on the number of data points). Antibodies below the threshold were excluded from further analysis. 70 antibodies passed the 99% confidence threshold in sets I & 2 and 84 antibodies passed the threshold in sets 3 & 4. An additional data processing step is normalization, which will be performed according to optimized procedures that we described in a recent publication (1) . Therefore the data used for the statistical analyses of Task 3 are high quality and reliable.
Additional progress toward the samples could be recognizing the antibodies based on the species of origin, rather than on the specificities of the antibodies. To further test this hypothesis, we spotted non-specific IgG (acquired from non-immunized animals) from rabbit, mouse, goat, sheep, and chicken, and we observed the correlations in the data from these non-specific antibodies to the data from the specific antibodies of the corresponding animal of origin. The binding patterns from the non-specific antibodies correlated with certain specific antibodies of the corresponding species, showing the existence of some species-specific binding in the samples.
To counteract this effect, we sought to block the species-specific binding by the addition of the normal, non-specific IgGs to the diluted serum samples. We added varying concentrations of antibodies from chicken, mouse, rabbit, goat and sheep to each of the serum samples and observed the change in binding to spotted antibodies. The binding to the non-specific antibodies was eliminated with the addition of the Uff r-': . P r.
was not significantly improve the accuracy and usefulness of the data from some antibodies, and it may reduce low levels of non-specific binding to most of the antibodies. We plan to run the profiling experiments again with the inclusion of the new blocking mix. A manuscript describing this technique is in preparation.
Use of multiplexed sandwich immunoassays for data collection. Another observation we made from previous experiments was that the detection limits of the two-color competitive assays may not be low enough to enable the routine measurements of low-abundance proteins and cytokines in serum. In the two-color assay, all proteins are labeled, and all non-specific binding to the surface or to the antibodies is detected. Low levels of this non-specific binding will negatively affect the detection limit. For example, the non-specific complement C3 binding to many of the antibodies that we observed in the experiments described under Task 1, step d, may have that effect. The two-color assay is very good at accurately and reproducibly detecting changes in mid-to-high abundance proteins, as demonstrated in previous work (2-4), but higher specificity is likely needed to measure low abundance proteins.
The best way to achieve higher specificity is to use a sandwich assay, which uses two antibodies per target-a capture antibody and a detection antibody. To use sandwich assays in a microarray format, multiple capture antibodies are spotted down, unlabeled serum is incubated on the array, and the binding to each antibody is detected using a cocktail of labeled detection antibodies, each antibody corresponding to one of the capture antibodies. Sandwich assays are technically more difficult than our standard assay, especially in a multiplexed format, so this format will be used for a smaller, select set of targets. We have already developed and validated several assays. For example, we tested several conditions to optimize a microarray assay for HGF (in collaboration with Dr. Brian Cao at VARI) and achieved standard curves with good linearity and detection limits (Figure 7) . We are developing a multiplexed sandwich assay for approximately 15 other targets (partly funded through another project). These assays will be used to profile the sample sets in year 3.
Another approach to acquiring sandwich immunoassay data on multiple low-level proteins is to use the Luminex bead-based platform. whether to pursue the use of this platform further.
Summary of progress on Task 3
The statement of work for Task 3 is: These items are scheduled to begin in the third year, but we have begun them in the second year to learn more about the data we are generating and to identify possible changes we need to make in acquiring additional data. For example, our initial analyses identified the species-specific binding that was described under Task 2. Our initial data sets and analyses are also identifying the antibodies that give valuable information about the samples. These antibodies will be used in subsequent data sets and will be further validated using other methods.
The initial analysis consisted of identifying antibodies with binding profiles that were statistically different between the sample groups. Using the data from sets I & 2, t-tests were performed on the data from each antibody to evaluate the differences between the patient classes (organ-confined prostate cancer, non-organ-confined prostate cancer, BPH, and healthy). The individual sets 1 & 2 and the averaged data from the two sets was analyzed. Several antibodies showed differences between the groups ( Table 2 ). Many of the differences had been previously observed or were consistent with literature reports. For example, we previously observed elevated von Willebrand factor, elevated alpha I -antichymotrypsin, and reduced immunoglobulin in prostate cancer (3). Reduced alpha-2-macroglobulin, elevated HGF, and higher IL-8 also have been observed. The elevated HGF is particularly interesting, since it is a ligand for Met receptor, which is important for driving prostate cancer metastasis to bone. We will use our sandwich assay to confirm and further explore that finding. Alpha-2-macroglobulin and alpha-1-antichymotrypsin both bind and inhibit prostate-specific antigen, and the measurement of those molecules together along with PSA could be valuable in multiparametric classification classes (to identify possible coregulation or functional relationships). Our next data sets will be collected using antibodies that have produced reproducible and informative results in the first data sets, and they will be performed using our improved methods. In addition, we will collect data using sandwich immunoassays for a selected set of antigens. Those data will be combined with the data from the two-color assays. The binding specificities of the important antibodies in the analyses will be characterized and validated. With the technical improvements that we have made to the assays, we expect to achieve high quality and informative data. "* Further development and improvement of the methods. We instituted improved quality control for the antibodies, improved our ability to run samples in high-throughput, and improved the data quality through the use of a better-performing surface. "• Identified the existence of species-dependent, non-specific binding and developed methods to block that effect. We showed that the inclusion of immunoglobulin blockers in the serum dilution buffer removes non-specific, species-dependent binding while maintaining normal levels of specific binding.
"* Pursued an alternate strategy to allow more specific and sensitive detection of a select set of analytes. Multiplexed sandwich immunoassays are being developed in-house for 15 analytes, and data from a commercial platform providing analysis of 33 analytes is being evaluated. "* Completed replicate profiling of multiple analytes on sets of serum samples from prostate cancer patients and controls. "* Identified many antibodies with statistically different levels between the patient groups, many previously observed and some new. Broad characterization of the immune responses elicited by tumors has valuable potential applications in diagnostics and in basic research. We present here the use of microarrays of tumor-derived proteins to profile the antibody repertoire in the sera of prostate cancer patients and controls. Rotofor isoelectric focusing and reversed-phase HPLC (20 x 88 fractions) were used to separate proteins from the prostate cancer cell line LNCaP into 1760 fractions, which were spotted in microarrays on coated microscope slides. The microarrays were incubated with serum samples from 51 men with prostate cancer and 46 male controls, in duplicate. The amount of bound immunoglobulin from each serum sample at each fraction was quantified by incubating biotinylated anti-human Ig on the microarrays, followed by Cy3-1abeled streptavidin. Multiple fractions had significantly and reproducibly higher levels of immunoglobulin binding in the prostate cancer samples compared with controls. 62 fractions had high antibody reactivity in at least five of the cancer patients but no more than one of the control patients. Many of the 62 fractions likely represent the same protein, since they appeared in distinct clusters in the fractionation. The level of immunoreactivity varied between patients, ranging from some patients with no reactivity to others with broad reactivity to many proteins. The breadth of the immune response among the cancer patients did not correlate with PSA level, Gleason grade, or stage of disease. Western blots, immunoprecipitations, and LC-MS methods are being used to identify the immunoreactive proteins. Identification and isolation of these proteins will facilitate more precise characterization of the specificity and prevalence of the immune responses in cancer patients. A complementary approach using antibody microarrays to detect serum protein profiles is being combined with these antigen microarrays to enhance tumor antigen and auto-antibody discovery for prostate cancer diagnosis. Microarrays of fractionated proteins could be a powerful tool for tumor antigen discovery and cancer diagnosis. Supported by Michigan Economic Development Corporation grant GR356 and Department of Defense grant 17-03-1-0044.
Protein Biomarkers abstract, September 2004
Antibody microarrays and two-color rolling circle amplification for probing cancer-associated serum protein profiles
The profiling of proteins in biological samples using antibody microarrays has the potential to yield new discoveries. In a step toward further enabling that capability, we developed the use of two-color rolling-circle amplification (Two-Color RCA) to measure the relative levels of proteins from two serum samples that have been captured on antibody microarrays. We are using this tool to study the associations of many circulating tumor and host response markers with a variety of cancers. The presentation will cover the performance and optimal use of the technology, in addition to the biological significance and potential clinical usefulness of the observed protein alterations in the sera of cancer patients.
Principal Investigator: Haab, Brian B.
American Chemical Society abstract, June 2004
Antibody microarrays enable highly multiplexed and rapid protein measurements in low sample volumes. The profiling of proteins in sera and other bodily fluids using this tool should offer new opportunities for biomarker discovery and insights into disease biology. Robotically spotted microarrays of antibodies and proteins were used to measure the relative abundances of multiple proteins in serum samples from prostate cancer and pancreatic cancer patients and controls. Serum proteins that had been coupled to either a fluorescent tag (e.g. Cy3) or a hapten (e.g. biotin) were incubated on the microarrays, and specific proteins bound to the immobilized molecules on the microarrays through specific interactions. After washing away unbound proteins, bound proteins were detected using the fluorescent tag or amplified signal (using rolling circle amplification, RCA) from the hapten-labeled proteins. RCA significantly enhanced detection sensitivity while maintaining the accuracy and precision of the measurements. Measurements of dozens of proteins in sera from cancer patients and controls revealed significant differences in protein abundances between the two sample groups. The biological significance and potential clinical usefulness of the observed protein alterations in the sera of cancer patients will be discussed.
